Summary

The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear cell component at intermediate-high or high risk for recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. Welireg includes a boxed warning for embryo-fetal toxicity and warnings and precautions for anemia and hypoxia.

AI summaries can be wrong sometimes—always verify important details using the source article.